survivin + MAGE-A3

**Survivin + MAGE-A3** refers to a combination immunotherapy approach targeting the cancer-testis antigens survivin (BIRC5) and MAGE-A3, both overexpressed in various cancers including multiple myeloma, NSCLC, melanoma, HCC, and pancreatic cancer. These antigens are leveraged in peptide vaccines or recombinant protein formulations with adjuvants like AS02B or AS15 to elicit antigen-specific CD8+ T-cell responses for anti-tumor immunity. No approved product exists under this exact name; instead, separate vaccines (e.g., GSK's recombinant MAGE-A3 protein + AS02B, code GSK1572932A) have been tested, while survivin + MAGE-A3 combinations appear in investigational multi-peptide vaccines post-ASCT for multiple myeloma to boost immune responses via TLR agonists like Poly-ICLC. Developers include GlaxoSmithKline (GSK) for MAGE-A3 components; primary indications explored are adjuvant therapy in resected NSCLC and melanoma, though phase III trials (MAGRIT, DERMA) failed to show DFS/OS benefits.

Other names

recombinant MAGE-3 plus recombinant SurvivinMAGE-3/Survivin vaccine